Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Myriad Enters Companion Diagnostics Field With An FDA First

This article was originally published in The Gray Sheet

Executive Summary

Myriad Genetics' BRCA1/2 gene testing service has been approved as a companion diagnostic to AstraZeneca's new ovarian cancer drug, an important step in the company's diversification plan and a significant milestone in FDA's oversight of laboratory-developed tests.


Related Content

Myriad's myChoice To Be Used In More Cancer Clinical Trials
More Companion Diagnostic Deals For Qiagen And Myriad
Making The Most Of A Maturing Myriad Genetics
Public, Academic Labs Press FDA To Be Flexible In LDT Requirements
FDA Plan To Regulate LDTs Includes Long Phase-In, Unmet-Need Exceptions
ASCO 2014: Oncology Companion Diagnostics Market Poised For Growth
Diagnostic Companies Rush To Test Formerly Off-Limit Genes


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts